arrow
Z

Zoi Bousiou

g. papanicolaou hospital
H指数:10
被引数:417

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Longitudinal Cognitive Assessment After CAR-T Cell Immunotherapy: A Prospective Cohort Study

CAR-T细胞免疫疗法后的纵向认知评估:一项前瞻性队列研究

Cancers
IF4.4
2026-06-010
OA
Treosulfan-Based Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Other Myeloid Malignancies

基于TREOSULFAN的异基因造血细胞移植预处理方案在急性髓系白血病和其他髓系恶性肿瘤中的应用

2025-10-290
OAAI
Survival Prediction in Allogeneic Haematopoietic Stem Cell Transplant Recipients Using Pre- and Post-Transplant Factors and Computational Intelligence

异基因造血干细胞移植受者生存预测:基于移植前后的因素和计算智能

2025-08-270
OAAI
Bloodstream Infections Due to Multidrug-Resistant Gram-Negative Organisms in Hematopoietic Stem Cell Transplant Recipients: A Multicenter Case-Control Study in a High-Prevalence Area

多重耐药革兰阴性菌引起的血流感染在造血干细胞移植受者中的发生:一项在高流行地区的多中心病例对照研究

2025-05-140
OAAI
Nationwide Multicenter Real-World Survey of CAR-T Cell Toxicity Prophylactic and Treatment Management Strategies

全国多中心真实世界CAR-T细胞毒性预防及治疗管理策略调查

BLOOD
IF23.1
2024-11-050
PRE
Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients

可溶性尿激酶型纤溶酶原激活剂受体(suPAR)和生长分化因子-15(GDF-15)水平与CAR-T细胞受体受者的内皮损伤指标显著相关。

BLOOD
IF23.1
2024-11-050
PRE
Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease

遗传易感性在窦状梗阻综合征/静脉闭塞性疾病中的作用

BLOOD
IF23.1
2024-11-050
PRE
Safety and Efficacy of Extracorporeal Photopheresis for Acute and Chronic Graft-versus-Host Disease

体外光穿刺术治疗急性和慢性移植物抗宿主病的安全性和有效性

2024-09-270
OAAI
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial

SARS-CoV-2-specific T细胞治疗严重COVID-19: 一项随机1/2期临床试验

2023-07-1718
PRE
Survival Advantage of Treosulfan Plus Fludarabine Before Allogeneic Hematopoietic Cell Transplantation for Older or Comorbid Patients With Myeloid Malignancies

Treosulfan联合氟达拉滨在老年或合并髓系恶性肿瘤患者异基因造血干细胞移植前的生存优势

2021-11-017
OAAI
Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis

brentuximab vedotin对自体干细胞移植后复发或进展的经典霍奇金淋巴瘤患者总生存期的积极影响: 一项全国性分析

2018-06-086
PREAI
Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study
2018-06-0527
PREAI
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
2017-02-2013
OAAI